Business
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
WALTHAM, Mass., October 20, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye dis
About this update from Hercules Capital, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/656f327461ff6daea05a170ccb0e7667"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ulL.3MCTeReehEP1SDk42A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/656f327461ff6daea05a170ccb0e7667","width":960,"height":240},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LI73IEkj24gAF7jUw6xBMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/656f327461ff6daea05a170ccb0e7667","width":1200,"height":300}},"lazy":false},{"type":"text","content":"- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval -","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"- Upfront and anticipated near-term milestones together with existing cash expected to fully fund the commercial launches of both veligrotug and VRDN-003 -","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"- Veligrotug Biologics License Application (BLA) submission expected imminently; VRDN-003 phase 3 clinical trial topline data readouts now expected Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 -","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"- Amended credit facility with Hercules Capital, Inc., providing additional access to capital at the company’s discretion based on milestone achievements -","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., October 20, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye disease (TED).","length":528,"tagName":"p"},{"type":"text","content":""We are excited to partner with DRI after a highly competitive royalty process. As...